Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB862,5863-0,23
PKN78,6278,73,22
Msft-0,07
Nokia4,78454,796-0,67
IBM0,56
Daimler AG74,2474,261,73
PFE-0,57
25.09.2021 2:04:00
Indexy online
AD Index online
select
AD Index online
 

  • 24.09.2021 21:59:37
Biocryst Pharm (BCRX.O, NASDAQ Cons)
Poslední obchod Změna (%) Změna (USD) Objem obchodů (ks)
14,93 -2,88 -0,44 1 860 228
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 26.09.2021
Popis společnosti
Obecné informace
Název společnostiBioCryst Pharmaceuticals, Inc.
TickerBCRX
Kmenové akcie:Ordinary Shares
RICBCRX.O
ISINUS09058V1035
Poslední známé roční výsledky31.12.2020
Poslední známé čtvrtletní výsledky30.06.2021
Počet zaměstnanců k 31.12.2020 246
Akcie v oběhu k 06.08.2021 178 869 928
MěnaUSD
Kontaktní informace
Ulice4505 Emperor Blvd Ste 200
MěstoDURHAM
PSČ27703-8457
ZeměUnited States
Kontatní osobaJohn Bluth
Funkce kontaktní osobyChief Communications Officer
Telefon19 198 591 302
Fax19198591314
Kontatní telefon19 198 597 910

Business Summary: BioCryst Pharmaceuticals, Inc. (BioCryst) is a commercial-stage biotechnology company that discovers small-molecule medicines. The Company focus on oral treatments for rare diseases in which unmet medical needs exist and an enzyme plays the key role in the biological pathway of the disease. ORLADEYO (berotralstat) is an oral, once-daily therapy that is approved in the United States, the European Union, Japan, and the United Kingdom for the prevention of hereditary angioedema (HAE) attacks in adults and pediatric patients 12 years and older. BioCryst has several ongoing development programs, including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases; BCX9250, an activin receptor-like kinase-2 (ALK-2) inhibitor for the treatment of fibrodysplasia ossificans progressiva, and Galidesivir, an antiviral drug for Marburg virus disease and Yellow Fever. RAPIVAB (peramivir injection) is a viral neuraminidase inhibitor for the treatment of influenza.
Financial Summary: BRIEF: For the six months ended 30 June 2021, BioCrystPharmaceuticals, Inc. revenues increased from $7.7M to$69M. Net loss increased 41% to $107.5M. Revenues reflectProduct sales increase from $218K to $51.3M. Higher netloss reflects Research and development increase of 66% to$95.3M (expense), Interest expense increase from $6M to$26.4M (expense), Interest and other income decrease of100% to $39K (income).
Odvětvová klasifikace
TRBC2009Biotechnology / Medical Research
TRBC2012Bio Therapeutic Drugs
RBSS2004Biotechnology
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICS2007Biological Product (exc Diagnostic) Mfg
NAICS2007Pharmaceutical Preparation Mfg
NAICS2007Research and Development in Biotechnology
NAICS1997Biological Product (except Diagnostic) Manufacturing
NAICS1997Pharmaceutical Preparation Manufacturing
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
SICBiological Prod's Not Diagnostic
SICBiological Prod's Not Diagnostic
SICPharmaceutical Preparations
SICCommercial Physical Research



  • Poslední aktualizace: 26.09.2021
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
President, Chief Executive Officer, DirectorJon Stonehouse6013.07.200705.01.2007
Chief Financial OfficerAnthony Doyle4102.04.202002.04.2020
Chief Communications OfficerJohn Bluth-
Chief Discovery OfficerYarlagadda Babu6823.12.2008
Chief Commercial OfficerCharles Gayer5015.01.202015.01.2020
Chief Medical OfficerWilliam Sheridan6601.07.200801.07.2008
Chief Research & Development OfficerHelen Thackray5222.03.202122.03.2021
Chief Legal Officer, Corporate SecretaryAlane Barnes5501.01.2013